ligos Therapeutics announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company’s stock to newly hired employees on December 9, in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
- Aligos Therapeutics presents pevifoscorvir, ALG-055009 data at HEP-DART
- Aligos Therapeutics: Strong Buy Rating Backed by Promising Liver Disease Treatments and Strategic Positioning
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics presents data from eight presentations at AASLD